GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

Novo Nordisk (NYSE:NVO) shares climbed 5.4% Friday after the U.S. Food and Drug Administration accepted the company’s New Drug Application for an oral version of Wegovy. If approved, the pill ...

Eli Lilly's stock suffered a nearly 12% loss in markets Thursday despite strong earnings, in what analysts say is an ...

Eli Lilly’s expanding US production and advancing pipeline offset near-term headwinds and support bullish conviction. Read ...

Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...

Danish drugmaker Novo Nordisk (NOV: N) has secured a significant advantage in the high-stakes obesity drug market after ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

The company’s health services division Evernorth is doubling down on a reliable growth area: assuaging payer concerns around ...

Analysts were rushing to reiterate their conviction in the stock following Thursday’s blow to Zepbound and Lilly shares.

Cigna (NYSE:CI) on Friday announced plans to launch a new specialized GLP-1 pharmacy called ENGUIDE from next month, as the ...